Bavarian Nordic (BAVA.CO), the Danish biotech company, announced on Thursday its potential to significantly increase the production of its mpox vaccine, with plans to supply 13 million doses by the end of 2025. This is an improvement from its previous forecast of 10 million doses. Furthermore, the company is actively exploring strategies to substantially boost its production capacity.
Bavarian Nordic revealed that it had identified measures to increase vaccine supply by an additional 50 million doses over the next 12-18 months, contingent on regulatory approvals and market demand.
“The expansion is largely dependent on demand. If the demand is present, and the necessary conditions are met, we have the capacity to raise production by another 50 million doses,” said Rolf Sass Sorensen, Bavarian’s Head of Investor Relations.
The urgency for increased vaccine supply follows the World Health Organization’s recent declaration of mpox as a global health emergency. Despite efforts to contain the spread of the disease, progress has been hindered by a shortage of vaccines, making Bavarian Nordic's potential ramp-up crucial for addressing this global health challenge.